Evercore ISI Upgrades Editas Medicine (EDIT) to Outperform

Evercore ISI analyst Liisa Bayko upgraded Editas Medicine (NASDAQ: EDIT) from Underperform to Outperform with a price target of $60.00 (from $20.00).

For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.

Shares of Editas Medicine closed at $46.05 yesterday.

You May Also Be Interested In

• Citi Upgrades a2 Milk Co (A2M:AU) (ACOPF) to Buy
• Citi Upgrades Angel Yeast Co Ltd (600298:CH) to Buy
• Misumi Group (9962:JP) PT Raised to JPY5,500 at Citi